肌肉内注射抗-D 治疗免疫性血小板减少症：单中心经验。
Intramuscular Anti-D treatment for immune thrombocytopenia: A single centre experience.
机构信息
Department of Hematology, Hospital Universitario de Canarias, La Laguna, Spain.
Department of Internal Medicine, Psychiatry and Dermatology, La Laguna University, La Laguna, Spain.
出版信息
Br J Haematol. 2023 Feb;200(3):353-357. doi: 10.1111/bjh.18484. Epub 2022 Oct 5.
Intravenous Anti-Rhesus-D immunoglobulin (Anti-D) is a first-line treatment option for immune thrombocytopenia in non-splenectomised and RhD-positive patients. In this report, we retrospectively review our experience with intramuscular (IM) Anti-D treatment in 74 adult patients between 1990 and 2018. We found that 73% of patients showed a response; almost all of them had complete responses (68.9%), and 26% achieved complete responses sustained at least 6 months after treatment discontinuation. [Correction added on 02 December 2022, after first online publication: In the preceding sentence, '(68.89%)' has been corrected to '(68.9%)' in this version.] No significant side effects were observed with no cases of acute haemolysis or anaemia reported. We conclude from this study that IM Anti-D is an effective and safe treatment for immune thrombocytopenia.
静脉注射抗 RhD 免疫球蛋白（Anti-D）是治疗非脾切除且 RhD 阳性免疫性血小板减少症的一线治疗选择。在本报告中，我们回顾性分析了 1990 年至 2018 年间 74 例成年患者接受肌肉内（IM）Anti-D 治疗的经验。我们发现 73%的患者有反应；几乎所有人都有完全反应（68.9%），26%的患者在治疗停止后至少 6 个月持续完全反应。[2022 年 12 月 2 日更正，首次在线出版后：在上一句中，（68.89%）已更正为（68.9%）。]未观察到明显的副作用，也未报告急性溶血或贫血病例。我们从这项研究中得出结论，IM Anti-D 是治疗免疫性血小板减少症的一种有效且安全的治疗方法。
Zotero 插件